IMA compared with ELDN: revenue, margins and what each company keeps, and the suppliers and customers both name

IMAImageneBio, Inc.

Mkt capRevenueRevenue

ELDNEledon Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

IMAImageneBio, Inc.

ELDNEledon Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IMA1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+0.70%—

ELDN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±32.7%▼−4.32%×0.13

May 14 '26±20.1%▲+1.80%×0.09

= impliedIMA realized, solidELDN realized, hatchedOne scale, both sides: full bar = 33%× = |realized| ÷ impliedSource: market data

Q1 FY26

±15.7%

▲+1.05%

×0.07

Q3 FY25±32.9%▼−7.95%×0.24

IMAImageneBio, Inc.

4.10▼−0.07%· post 4.10· delayed

Mkt cap$46.5MRevenue$800,000Q4 FY25

ELDNEledon Pharmaceuticals, Inc.

2.75▼−0.62%· post 2.63· delayed

After hoursNov 2 '26delayed

Mkt cap$225.1MRevenue—

Compare

After hoursNov 2 '26delayed

IMAImageneBio, Inc.

ELDNEledon Pharmaceuticals, Inc.

4.10▼−0.07%post 4.10delayed

Price

2.75▼−0.62%post 2.63delayed

$46.5M

Mkt cap

$225.1M

Q4 FY25$800,000

Revenue

—

IMA4.10▼−0.07%vsELDN2.75▼−0.62%After hoursNov 2 '26delayed